2,079 reports of this reaction
2.0% of all PIMAVANSERIN TARTRATE reports
#10 most reported adverse reaction
HALLUCINATION, VISUAL is the #10 most commonly reported adverse reaction for PIMAVANSERIN TARTRATE, manufactured by Acadia Pharmaceuticals Inc.. There are 2,079 FDA adverse event reports linking PIMAVANSERIN TARTRATE to HALLUCINATION, VISUAL. This represents approximately 2.0% of all 106,130 adverse event reports for this drug.
PIMAVANSERIN TARTRATE has an overall safety score of 85 out of 100. Patients taking PIMAVANSERIN TARTRATE who experience hallucination, visual should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HALLUCINATION, VISUAL is a less commonly reported adverse event for PIMAVANSERIN TARTRATE, but still significant enough to appear in the safety profile.
In addition to hallucination, visual, the following adverse reactions have been reported for PIMAVANSERIN TARTRATE:
The following drugs have also been linked to hallucination, visual in FDA adverse event reports:
HALLUCINATION, VISUAL has been reported as an adverse event in 2,079 FDA reports for PIMAVANSERIN TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HALLUCINATION, VISUAL accounts for approximately 2.0% of all adverse event reports for PIMAVANSERIN TARTRATE, making it a notable side effect.
If you experience hallucination, visual while taking PIMAVANSERIN TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.